IMPORTANT NOTE:
Unless otherwise indicated, this policy will apply to all lines of business.

Even though this policy may indicate that a particular service or supply may be considered medically necessary and thus covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit plan contains its own specific provisions for coverage and exclusions. Not all benefits that are determined to be medically necessary will be covered under the terms of your benefit plan. You need to consult the Evidence of Coverage (EOC) or Summary Plan Description (SPD) to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and your plan of benefits, the provisions of your benefits plan will govern. However, applicable state mandates will take precedence with respect to fully insured plans and self-funded non-ERISA (e.g., government, school boards, church) plans. Unless otherwise specifically excluded, Federal mandates will apply to all plans. With respect to Medicare-linked plan members, this policy will apply unless there are Medicare policies that provide differing coverage rules, in which case Medicare coverage rules supersede guidelines in this policy. Medicare-linked plan policies will only apply to benefits paid for under Medicare rules, and not to any other health benefit plan benefits. CMS’s Coverage Issues Manual can be found on the CMS website. Similarly, for Medicaid-linked plans, the Texas Medicaid Provider Procedures Manual (TMPPM) supersedes coverage guidelines in this policy where applicable.

SERVICE: Ventricular Assist Devices and Artificial Heart
Also Known as: Left Ventricular Assist Devices, Percutaneous Left Ventricular Assist Devices, Right Ventricular Assist Devices, Total Artificial Heart

PRIOR AUTHORIZATION: Required.

POLICY: Please review the plan’s EOC (Evidence of Coverage) or Summary Plan Description (SPD) for coverage details.

For Medicare plans, please refer to appropriate Medicare LCD (Local Coverage Determination). If there is no applicable LCD, use the criteria set forth below.

For Medicaid plans, please confirm coverage as outlined in the Texas Medicaid TMPPM.

SWHP/FC may consider a TAC-approved (see below) and FDA-approved ventricular assist device (VAD) medically necessary for 1 or more of the following FDA-approved indications:
- Post-cardiotomy. VADs used for support of blood circulation post-cardiotomy are covered only if they have received approval from the Food and Drug Administration (FDA) for that purpose, and the VADs are used according to the FDA-approved labeling instructions; OR
- As a bridge to transplant for members who are not expected to survive until transplantation AND are awaiting heart transplantation as evidenced by listing on the waitlist of the Organ Procurement and Transplantation Network (see exclusions below); OR
- As destination therapy when all of the following criteria are met:
  - The device has received FDA approval for a destination therapy indication; AND
  - Member has New York Heart Association (NYHA) Class IV end-stage ventricular heart failure and is NOT a candidate for heart transplant; AND
  - Member has failed to respond to optimal medical management (including beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors if tolerated) for at least 45 of the last 60 days, or has been balloon pump dependent for 7 days, or has been IV inotrope dependent for 14 days; AND
MEDICAL COVERAGE POLICY

SERVICE: Ventricular Assist Devices (VAD) and Artificial Heart

Policy Number: 201

Effective Date: 07/01/2020

Last Review: 05/28/2020

Next Review Date: 05/28/2021

- Has a left ventricular ejection fraction (LVEF) less than 25%; AND
- Has demonstrated functional limitation with a peak oxygen consumption of less than or equal to 14 ml/kg/min (Note: This criterion may be waived in persons who are unable to perform exercise stress testing).

SWHP/FC may consider total artificial hearts (TAH) medically necessary as a bridge to heart transplantation for patients with biventricular failure who have no other reasonable medical or surgical treatment options and 1 or more of the following:
- Are currently listed as heart transplantation candidates; OR
- Are undergoing evaluation for heart transplantation and are not expected to survive until a donor heart can be obtained.

Percutaneous ventricular assist devices (pVADs) that are FDA approved may be considered medically necessary for 1 or more of the following FDA approved indications:
- Impella® - partial circulatory support using an extracorporeal bypass control unit, for periods up to 6 hours; OR
- TandemHeart® - temporary left ventricular bypass of 6 hours or less.

SWHP/FC may consider FDA-approved right ventricular assist devices (RVADs): e.g., the CentriMag Right Ventricular Assist System) medically necessary for temporary circulatory support when all of the following criteria are met:
- RVAD is used for up to 30 days for members in cardiogenic shock due to acute right ventricular failure; AND
- Member is willing and able to be treated with an anticoagulant

SWHP/FC may consider FDA approved pediatric ventricular assist devices medically necessary when ALL of the following are met:
- Child has documented end-stage left ventricular failure
- An age appropriate VAD will be used until a donor heart can be obtained

Current FDA-approved pediatric VADs include the Berlin Heart EXCOR Pediatric Ventricular Assist Device (for children aged 16 years or younger) and the HeartAssist 5 Pediatric Ventricular Assist Device (for children aged 5 to 16 years). The EXCOR Pediatric VAD can be used in children up to 60 kg body weight. The HeartAssist 5 Pediatric VAD can be used in children with a BSA greater than or equal to 0.7 m² and less than 1.5 m²).

Exclusions:

SWHP/FC does NOT consider a VAD for any other reason as medically necessary and is considered experimental, investigational or unproven.

Xenotransplantation/heterotransplantation (a graft transplantation between different species) of a baboon heart OR porcine/swine (pig) heart is considered experimental, investigational and/or unproven as bridge to transplantation.
OVERVIEW:

VADs may be useful for short-term (days), intermediate (weeks) and long-term (months to years) use. Short-term assisted circulation is used to facilitate the performance of complex coronary interventional procedures and as a bridge to recovery in postcardiotomy patients who cannot be weaned off cardiopulmonary bypass, individuals in cardiogenic shock, patients with low cardiac output after cardiac surgery and individuals with acute rejection after heart transplant.

Devices for intermediate and long-term use are implanted as intracorporeal devices and are commonly used as a bridge to transplantation (BTT), a bridge to recovery (BTR) when heart transplantation is not indicated and it is anticipated that the individual may recover, and as destination therapy (individuals who are inappropriate for heart transplant and in whom no return to adequate cardiac functioning is expected).

In general, VADs may facilitate myocardial recovery for individuals with reversible ventricular dysfunction, temporarily maintain circulation until transplant, or extend the length and quality of life in the terminally ill.

MANDATES:

There are no mandated benefits or regulatory requirements for SWHP/FC to provide coverage for these services.

SUPPORTING DATA:

Medical Exclusions:

Contraindications for bridge to transplant LVADs include conditions that would generally exclude patients for heart transplant, such as chronic irreversible hepatic, renal, or respiratory failure, morbid obesity (BMI >35), life expectancy (in the absence of cardiovascular disease) less than 2 years, systemic infection (including HIV), and malignancies or blood dyscrasia. Due to potential problems with adequate function of the VAD, implantation is also contraindicated in patients with uncorrected valvular disease.

Contraindications to heart transplant:

1. New York Heart Association (NYHA) classification of heart failure I or II (see below),
2. Member does not have potential for conditioning and rehabilitation after transplant (i.e., member is moribund or morbidly obese);
3. Life expectancy (in the absence of cardiovascular disease) is less than 2 years;
4. Presence of malignancy (except for non-melanomatous skin cancers);
5. Inadequate pulmonary, liver and renal function;
6. Active infections that are not effectively treated, including HIV infection;
7. Presence of active or recurrent pancreatitis;
8. Diabetes with severe end-organ damage (neuropathy, nephropathy with declining renal function and proliferative retinopathy);
9. Uncontrolled and/or untreated psychiatric disorders that interfere with compliance to a strict treatment regimen; and
10. Active alcohol or chemical dependency that interferes with compliance to a strict treatment regimen.

Technical Assessment: TAC group approved:
(Intrathoracic only)
Impella 2.5 (Not 5.0)
Heartmate II/ Thoratec
TandemHeart (intrathoracic)

New York Heart Association (NYHA) Functional Classification of Heart Failure

NYHA Class Symptoms
I. No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.
II. Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
III. Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20–100 m). Comfortable only at rest.
IV. Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.


CODES:

<table>
<thead>
<tr>
<th>CPT Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>33927</td>
<td>Insertion of ventricular assist device, extracorporeal, single ventricle</td>
</tr>
<tr>
<td>33975</td>
<td>Insertion of ventricular assist device; extracorporeal, biventricular</td>
</tr>
<tr>
<td>33976</td>
<td>Removal of ventricular assist device; extracorporeal, single ventricle</td>
</tr>
<tr>
<td>33977</td>
<td>Removal of ventricular assist device; extracorporeal, biventricular</td>
</tr>
<tr>
<td>33978</td>
<td>Insertion of ventricular assist device; implantable intracorporeal, single</td>
</tr>
<tr>
<td></td>
<td>ventricle</td>
</tr>
<tr>
<td>33979</td>
<td>Removal of ventricular assist device; implantable intracorporeal, single</td>
</tr>
<tr>
<td></td>
<td>ventricle</td>
</tr>
<tr>
<td>33980</td>
<td>Replacement of extracorporeal ventricular assist device, single or biventricular, pump</td>
</tr>
<tr>
<td>33981</td>
<td>Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle, without cardiopulmonary bypass</td>
</tr>
<tr>
<td>33982</td>
<td>Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle, with cardiopulmonary bypass</td>
</tr>
<tr>
<td>33990</td>
<td>Insertion of ventricular assist device, percutaneous</td>
</tr>
<tr>
<td>33991</td>
<td>Insertion of ventricular assist device, percutaneous</td>
</tr>
<tr>
<td>33992</td>
<td>Removal of percutaneous ventricular assist device at separate and distinct session from insertion</td>
</tr>
<tr>
<td>33993</td>
<td>Repositioning of percutaneous ventricular assist device with imaging guidance</td>
</tr>
</tbody>
</table>

Ventricular Assist Devices
### MEDICAL COVERAGE POLICY

**SERVICE:** Ventricular Assist Devices (VAD) and Artificial Heart

<table>
<thead>
<tr>
<th>Policy Number:</th>
<th>201</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Effective Date:</strong></td>
<td>07/01/2020</td>
</tr>
<tr>
<td><strong>Last Review:</strong></td>
<td>05/28/2020</td>
</tr>
<tr>
<td><strong>Next Review Date:</strong></td>
<td>05/28/2021</td>
</tr>
</tbody>
</table>

### CPT Not Covered:

- 33927 Implantation of a total replacement heart system (artificial heart) with recipient cardiectomy
- 33928 Removal and replacement of total replacement heart system (artificial heart)
- 33929 Removal of a total replacement heart system (artificial heart) for heart transplantation
- 92970 Cardioassist-method of circulatory assist; internal
- 93750 Interrogation of ventricular assist device (VAD)

### HCPCS codes:

- Q0478
- Q0479
- Q0480
- Q0481
- Q0482
- Q0483
- Q0484
- Q0485
- Q0486
- Q0487
- Q0488
- Q0489
- Q0490
- Q0491
- Q0492
- Q0493
- Q0494
- Q0495
- Q0496
- Q0497
- Q0498
- Q0499
- Q0500
- Q0501
- Q0502
- Q0503
- Q0504
- Q0505
- Q0506

### ICD10:

- I11.0 Hypertensive Heart Disease with CHF
- I13.x Hypertensive Heart and Renal Disease with CHF
- I20 - I25 Ischemic Heart Diseases
- I42.x Cardiomyopathy
- I43.x Cardiomyopathy in other diseases
- I44.x Atrioventricular and left bundle branch block
- I45.x Other conduction disorders
- I48 Atrial fibrillation and flutter
- R57.0 Cardiogenic Shock

**CMS:**

NCD: Ventricular Assist Device (20.9.1) effective date – 10/30/2013.

There is no LCD. CMS published a decision memorandum liberalizing criteria for coverage of ventricular assist devices (CMS, 2010). The CMS policy removes body size criteria and eases restrictions around the required duration of failed medical therapy and peak oxygen consumption. Under the rule changes, CMS will reimburse ventricular assist devices as destination therapy when all of the following criteria are met:

1. The device to be implanted has received FDA approval for a destination therapy indication; and
2. Patient has NYHA Class IV end-stage ventricular heart failure and is not suitable for heart transplantation; and
3. Patient has failed to respond to optimal medical management (including beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors if tolerated) for at least 45 of the last 60 days (down from 60 of the prior 90 days in the earlier criteria), or patient has been balloon pump dependent for seven days, or patient has been IV inotrope dependent for 14 days; and
4. Patient has a left ventricular ejection fraction (LVEF) less than 25%; and
5. Patient has demonstrated functional limitation with a peak oxygen consumption of less than or equal to 14 ml/kg/min (increased from 12 ml/kg/min in the previous criteria).
MEDICAL COVERAGE POLICY

SERVICE: Ventricular Assist Devices (VAD) and Artificial Heart

Policy Number: 201
Effective Date: 07/01/2020
Last Review: 05/28/2020
Next Review Date: 05/28/2021

CMS policy: CAG-00162N (BTT) and CAG-00119R2 (DT)

POLICY HISTORY:

<table>
<thead>
<tr>
<th>Status</th>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>New</td>
<td>03/12/2012</td>
<td>New policy</td>
</tr>
<tr>
<td>Reviewed</td>
<td>02/14/2013</td>
<td>Reviewed.</td>
</tr>
<tr>
<td>Reviewed</td>
<td>05/30/2013</td>
<td>CMS reference added. ICD10 codes added.</td>
</tr>
<tr>
<td>Reviewed</td>
<td>05/22/2014</td>
<td>No changes</td>
</tr>
<tr>
<td>Reviewed</td>
<td>09/25/2014</td>
<td>Minor update to criteria based on updated NCD</td>
</tr>
<tr>
<td>Reviewed</td>
<td>05/28/2015</td>
<td>No changes</td>
</tr>
<tr>
<td>Reviewed</td>
<td>07/07/2016</td>
<td>Added FDA information and pediatric exclusion</td>
</tr>
<tr>
<td>Reviewed</td>
<td>06/13/2017</td>
<td>Expanded CMS information</td>
</tr>
<tr>
<td>Reviewed</td>
<td>01/16/2018</td>
<td>Added coverage criteria for artificial heart. Updated other criteria</td>
</tr>
<tr>
<td>Reviewed</td>
<td>01/08/2019</td>
<td>Minor corrections</td>
</tr>
<tr>
<td>Updated</td>
<td>01/23/2020</td>
<td>Added criteria for percutaneous VAD and right heart VAD</td>
</tr>
<tr>
<td>Updated</td>
<td>05/28/2020</td>
<td>Reviewed and aligned for FirstCare and SWHP</td>
</tr>
</tbody>
</table>

REFERENCES:

The following scientific references were utilized in the formulation of this medical policy. SWHP will continue to review clinical evidence related to this policy and may modify it at a later date based upon the evolution of the published clinical evidence. Should additional scientific studies become available and they are not included in the list, please forward the reference(s) to SWHP so the information can be reviewed by the Medical Coverage Policy Committee (MCPC) and the Quality Improvement Committee (QIC) to determine if a modification of the policy is in order.